MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

MDT

96.67

+0.59%↑

A

137.56

-0.2%↓

VEEV

224.65

-0.07%↓

HQY

91.97

-0.76%↓

PHR.US

17

+0.18%↑

Search

Teva Pharmaceutical Industries Ltd.

Cerrado

SectorSanidad

31.34 -0.73

Resumen

Variación precio

24h

Actual

MĆ­nimo

31.3

MƔximo

31.62

MƩtricas clave

By Trading Economics

Ingresos

152M

434M

Ventas

304M

4.5B

P/B

Media del Sector

51.164

78.892

BPA

0.78

Margen de beneficios

9.688

Empleados

33,892

EBITDA

449M

1.1B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+5.24% upside

EstadĆ­sticas de Mercado

By TradingEconomics

Capitalización Mercado

12B

36B

Apertura anterior

32.07

Cierre anterior

31.34

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

60 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Teva Pharmaceutical Industries Ltd. GrƔfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

9 oct 2025, 09:10 UTC

Acciones populares

Stocks to Watch Thursday: HSBC, PepsiCo, MP Materials -- WSJ

7 may 2025, 17:01 UTC

Principales Noticias

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

Comparación entre iguales

Cambio de precio

Teva Pharmaceutical Industries Ltd. previsión

Precio Objetivo

By TipRanks

5.24% repunte

Estimación a 12 Meses

Media 33.56Ā USDĀ  5.24%

MÔximo 40 USD

MĆ­nimo 29Ā USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Teva Pharmaceutical Industries Ltd. Dist en los Ćŗltimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

10

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

15.58 / N/ASoporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

60 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.